Model N Responds To Mounting Regulatory Pharma Pressures With Innovations That Ensure Compliance And Optimize Revenue
Portfolio Pulse from Benzinga Newsdesk
Model N (NYSE:MODN) has announced new product enhancements to help pharma manufacturers manage regulatory, compliance, and discounting challenges. The enhancements relate to 340B, the Inflation Reduction Act (IRA), and global pricing. The company has also added IRA-specific master data attributes to its product master data, and introduced Country Rules as a Service to its Global Pricing Management product to help pharma companies comply with evolving regulations worldwide.
November 07, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Model N's new product enhancements and services are designed to help pharma manufacturers navigate regulatory, compliance, and discounting challenges. This could potentially increase the company's customer base and revenue.
Model N's new product enhancements and services are directly aimed at helping pharma manufacturers navigate the increasingly complex regulatory environment. This could potentially attract more customers to the company, thereby increasing its revenue. The company's proactive approach to addressing industry challenges also demonstrates its commitment to innovation and customer service, which could further enhance its reputation and market position.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100